- July/August 2015
Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
- June 2015
Lesley Seymour and Jan Bogaerts on the future of RECIST.
- May 2015
Paul Workman on strategies for overcoming resistance to new drugs.
- April 2015
Highlights from the TAT Congress in Paris.
- March 2015
Christopher Wild on the exposome, a measure of environmental exposure.
- February 2015
Mathematicians are developing a blood flow model for metastasis.
- January 2015
René Bernards on discovering effective drug combinations.
- December 2014
Research on the high rate of burnout among young oncologists.
- November 2014
Carl June on the efficacy of CAR-T cells in treating leukaemia.
- October 2014
News from ESMO 2014 with Solange Peters and Alexander Eggermont.
- September 2014
Discussing how healthcare systems can meet the needs of cancer survivors.
EJC News Focus – October 2013
'New ways of learning are needed' as personalised medicine enters routine practice
Prospective observational registries, which record every clinical encounter with every patient, are going to be the way to continue progress in our understanding of cancer, according to Richard L Schilsky, Chief Medical Officer of the American Society of Clinical Oncology (ASCO).
Genetic characterisation has led to cancers which were traditionally considered common becoming instead a collection of rare diseases. It means that there are now too many cancers, too many drugs in development and not enough patients, time or money to study everything by doing clinical trials, he says.
In this month's EJC News Focus, Schilsky tells Helen Saul that as personalised medicine enters the clinic, changes are needed – and are happening – in research, development and the regulation of new cancer drugs.